Table 5.

Multivariate analysis for recurrence-free survival in patients with grade 1–2, stage I–II endometrioid endometrial cancer evaluating a combination of CTNNB1 and TP53 mutations.^a

Characteristic	Hazard Ratio	95% Confidence Interval	p-value
Age at diagnosis	1.06	1.03 – 1.09	< 0.001
BMI	1.00	0.96 – 1.03	0.87
Myometrial invasion (≥ 50%)	0.86	0.39 – 1.90	0.72
LVSI	1.83	0.84 – 3.99	0.13
Tumor size	0.95	0.81 – 1.12	0.57
Adjuvant therapyb	0.78	0.37 – 1.65	0.51
CTNNB1 or TP53 mutation	4.69	2.38 – 9.24	< 0.001

^a125 patients had the above information available and were included in the analysis

^bAdjuvant treatment was treated as a time-dependent covariate